| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7220862 | PFIZER | Calcitonin gene related peptide receptor antagonists |
Jan, 2024
(3 months ago) | |
| US8481546 | PFIZER | CGRP receptor antagonist |
Oct, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7314883 | PFIZER | Anti-migraine treatments |
Dec, 2023
(4 months ago) | |
Zavzpret is owned by Pfizer.
Zavzpret contains Zavegepant Hydrochloride.
Zavzpret has a total of 3 drug patents out of which 2 drug patents have expired.
Expired drug patents of Zavzpret are:
- US7314883
- US7220862
Zavzpret was authorised for market use on 09 March, 2023.
Zavzpret is available in spray, metered;nasal dosage forms.
Zavzpret can be used as administration of zavegepant for acute treatment of migraine with or without aura.
Drug patent challenges can be filed against Zavzpret from 10 March, 2027.
The generics of Zavzpret are possible to be released after 07 October, 2031.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Mar 09, 2028 |
Drugs and Companies using ZAVEGEPANT HYDROCHLORIDE ingredient
NCE-1 date: 10 March, 2027
Market Authorisation Date: 09 March, 2023
Treatment: Administration of zavegepant for acute treatment of migraine with or without aura
Dosage: SPRAY, METERED;NASAL
ZAVZPRET family patents
